Royalty Buy-Down. Rhythm shall have the right on a Product-by-Product basis, exercisable at any time during a period beginning on the First Commercial of the applicable Product and ending on the [ ]* anniversary thereof, to buy down the Royalties to a flat rate of [ ]* on Net Sales of such Product by making payment to Camurus of a one-time non-refundable and non-creditable amount of [ ]*. The reduced royalty rate shall apply to all Net Sales of such Product from the calendar quarter following the calendar quarter in which said lump-sum payment is received by Camurus. Any sales milestones that would otherwise become due pursuant to Section 5.4 after the calendar quarter in which said payment was received by Camurus, shall no longer be payable.
Royalty Buy-Down. At any time prior to the initiation of the first Phase III Clinical Trial of a Product by or on behalf of GSK, GSK shall have the right, at its sole discretion, to buy down the royalty percentages set forth in Section 4.5.1, solely with respect to such Product, from […***…]%, […***…]% and […***…]%, respectively, to a floor of […***…]%, […***…]% and […***…]% by making a one-time payment of Ten Million U.S. Dollars ($10,000,000) for such Product.
Royalty Buy-Down. At any time during the period commencing on the Effective Date and expiring [ * ] after obtaining Regulatory Approval for marketing Product in the United States (the “Option Period”), ARCA shall have the option to buy-down the royalty rates set forth in Section 5.2.1 (i) as follows: For annual Net Sales over [ * ], and up to [ * ], ARCA shall have the option to buy-down up to two and one-half (2 1/2) percentage points (down to a rate of 7.5%), and for annual Net Sales over [ * ], ARCA shall have the option to buy-down up to eight (8) percentage points (down to a rate of 12%). To exercise the buy-down option, ARCA shall provide CPEC with a written notice electing to exercise the buy-down option at any time during the Option Period and, within [ * ] thereafter, pay to CPEC [ * ] reduction in royalty rate. The applicable royalty rate reduction shall be effective as of the date the related payment is made in full to CPEC.”
Royalty Buy-Down. At any time prior to the first dosing of a patient in a Phase III Clinical Trial for a Product, Celgene will have the right to buy down the Royalty for such Product to a minimum of […***…] ([…***…]%) at all sales levels, by providing Zymeworks with written notice specifying the Product for which it desires to buy down such Royalty together with a payment of Ten Million US Dollars (USD $10,000,000) per percentage point buy down. Accordingly, a single payment of Ten Million US Dollars (USD $10,000,000) pursuant to this Section 5.6.3 would reduce the Royalty rates applicable to such Product down to […***…]% (Tier A), […***…]% (Tier B), and […***…]% (Tier C). An aggregate payment of Twenty Million US Dollars (USD $20,000,000) would reduce the Royalty rates applicable to such Product down to […***…]% (Tier A), […***…]% (Tier B), and […***…]% (Tier C). An aggregate payment of Thirty Million US Dollars (USD $30,000,000) would reduce the Royalty rates applicable to such Product down to […***…]% (Tier A), […***…]% (Tier B), and […***…]% (Tier C). For clarity, the Royalty buy-down shall apply on a Product-by-Product basis.
Royalty Buy-Down. Pursuant to Section 4.5(b) of the Adimab Agreement, on an Adimab Product-by-Adimab Product basis, at any time prior to the first dosing of a patient in a Phase III Clinical Trial with a particular Adimab Product, TIANSHI may, at its sole discretion, make a one-time payment of [***] dollars ($[***] ) to CASI, and thereafter, notwithstanding the royalty rates set forth in Section 4.5 of the Adimab Agreement, with respect to such Adimab Product, the royalty rate will be [***] % instead of the royalty rates set forth in Section 4.5(a) of the Adimab Agreement, subject to further adjustment as set forth in Section 4.5(c) of the Adimab Agreement, as applicable.
Royalty Buy-Down. 6.1 The Issuer represents and warrants to the Purchaser that the Xxxxx Gold Project is currently subject to a 5% gross royalty on gold and silver produced and a 4% net smelter returns royalty on all other metals (collectively the “Waterton Royalty”) in favor of Waterton pursuant to that certain quitclaim deed with reservation of royalty dated December 27, 2007 (the “Waterton Royalty Agreement”) as recorded in Lander County, Nevada on February 1, 2008 as Document No. 250304.
Royalty Buy-Down. At any time prior to the initiation of the first Phase III Clinical Trial of a […***…]161 Product by or on behalf of GSK, GSK shall have the right, at its sole discretion, to buy down the royalty percentages set forth in Section 4.5.1, solely with respect to such […***…]162 Product, from […***…]%163, […***…]%164 and […***…]%165, respectively, to a floor of […***…]%166, […***…]%167 and […***…]%168 by making a one-time payment of […***…]169 U.S. Dollars ($[…***…]170) for such […***…]171 Product. At any time prior to the 148 Competitive Information – Discovery Information and Technical Information. 149 Competitive Information – Discovery Information and Technical Information. 150 Competitive Information – Financial Provisions. 151 Competitive Information – Financial Provisions. 152 Competitive Information – Financial Provisions. 153 Competitive Information – Financial Provisions. 154 Competitive Information – Financial Provisions. 155 Competitive Information – Financial Provisions. 156 Competitive Information – Financial Provisions. 157 Competitive Information – Financial Provisions. 158 Competitive Information – Financial Provisions. 159 Competitive Information – Financial Provisions. 160 Competitive Information – Financial Provisions. 161 Competitive Information – Discovery Information and Technical Information. 162 Competitive Information – Discovery Information and Technical Information. 163 Competitive Information – Financial Provisions. 164 Competitive Information – Financial Provisions. 165 Competitive Information – Financial Provisions. 166 Competitive Information – Financial Provisions. 167 Competitive Information – Financial Provisions. 168 Competitive Information – Financial Provisions. 169 Competitive Information – Financial Provisions. 170 Competitive Information – Financial Provisions. 171 Competitive Information – Discovery Information and Technical Information. Execution Copy initiation of the first Phase III Clinical Trial of a […***…]172 Product by or on behalf of GSK, GSK shall have the right, at its sole discretion, to buy down the royalty percentages set forth in Section 4.5.1, solely with respect to such […***…]173 Product, from […***…]%174, […***…]%175 and […***…]%176, respectively, to a floor of […***…]%177, […***…]%178 and […***…]%179 by making a one-time payment of […***…]180 U.S. Dollars ($[…***…]181) for such […***…]182 Product.”
Royalty Buy-Down. 10.14.1 With respect to each Licensed Product, upon AbbVie’s written request (an “Adjustment Request”) at any time within [**] after the filing of the first BLA for such Licensed Product in the United States, the Parties shall meet to discuss in good faith an amendment to this Agreement pursuant to which AbbVie (or one of its Affiliates) would make a one-time payment to Voyager in exchange for a decrease in the royalties payable by AbbVie to Voyager pursuant to Section 10.3 (but not, for clarity, any decrease in any Milestone Payments payable by AbbVie to Voyager pursuant to Section 10.2) (the “Requested Decrease”); provided that the royalties payable by AbbVie to Voyager pursuant to Section 10.3 shall not be reduced to a royalty rate lower than [**] percent ([**]%) unless AbbVie’s royalty obligations are terminated in their entirety (a “Complete Reduction”), in which case the provisions of Section 10.14.5 shall apply (in addition to Sections 10.14.1 through 10.14.4). AbbVie may only make one (1) Adjustment Request pursuant to this Section 10.14.1 with respect to each Licensed Product.
Royalty Buy-Down. Buyer shall have the option, in Buyer’s sole discretion, to buy down the Royalty, as follows:
Royalty Buy-Down. Grantor shall have the option, in Grantor’s sole discretion, to buy down the Royalty, as follows:
